September 5, 2024 02:07 PM EDT
Pharma
Law

Ocali­va will con­tin­ue to be avail­able in the EU fol­low­ing Eu­ro­pean court's de­ci­sion

Katherine Lewin

News Reporter

Ad­vanz Phar­ma scored a win for its liv­er dis­ease treat­ment Ocali­va af­ter the Gen­er­al Court of the Eu­ro­pean Union tem­porar­i­ly sus­pend­ed the Eu­ro­pean Com­mis­sion’s de­ci­sion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times